Phase 2
N=85
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
Cystic Fibrosis
Bottom Line
View on ClinicalTrials.gov: NCT02465450 ↗Enrolled (actual)
85
Serious AEs
5.3%
Results posted
Feb 2018
Primary outcome: Primary: Number of Participants With Treatment Emergent Adverse Events. — 14; 13; 15; 21 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- JBT-101 (lenabasum) (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Corbus Pharmaceuticals Inc.
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment Emergent Adverse Events. |
14; 13; 15; 21; 19; 14 | — |
| SECONDARY JBT-101 (Lenabasum) Plasma Concentrations on Day 84 |
249.77; 360.80; 0.00 | — |
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).
Eligibility Criteria
Inclusion Criteria
- Documentation of a CF diagnosis as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 or more of the following criteria:
- Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test;
- Two well-characterized mutations in the CFTR gene
- FEV1 ≥ 40% predicted corrected
- Stable treatment of CF for 14 days before Visit 1
Exclusion Criteria
- Severe or unstable CF, such as:
- Intravenous antibiotic treatment within 14 days before Visit 1
- Treatment with any corticosteroids > 10 mg per day or > 20 mg every other day oral prednisone or equivalent within 14 days before Visit 1
- Any one of the following values for laboratory tests at Screening:
- A positive pregnancy test (or at Visit 1);
- Hemoglobin 2.5 x upper normal limit
- Total bilirubin ≥ 1.5 x upper limit of normal
- Any other condition that, in the opinion of the Principal Investigator, is clinically significant and may put the subject at greater safety risk, influence response to study product, or interfere with study assessments.
Data sourced from ClinicalTrials.gov (NCT02465450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.